Uchafu wa asidi ya amino inayotumika kwa synthesize protini
Maelezo ya bidhaa
| NO | Bidhaa | CAS hapana | Kiashiria muhimu cha ubora | |||
| Usafi | Max. uchafu | Jumla ya mabaki ya kutengenezea | Unyevu | |||
| 1 | FMOC-β-ALA-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | FMOC-D-ALA-D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | FMOC-β-Ala-D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | FMOC-Arg (PBF) -arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | FMOC-β-ALA-Arg (PBF) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | FMOC-D-Arg (PBF) -D-Arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | FMOC-β-Ala-D-Arg (PBF) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | FMOC-HOMOARG (PBF) -HOMOARG (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | FMOC-β-Ala-Homoarg (PBF) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | FMOC-ASN (trt) -asn (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | FMOC-β-ALA-ASN (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | FMOC-ASP (OTBU) -ASP (OTBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | FMOC-β-ALA-ASP (OTBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | FMOC-Cys (TRT) -CYS (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | FMOC-β-Ala-Cys (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | FMOC-Cys (ACM) -CYS (ACM) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | FMOC-β-Ala-Cys (ACM) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | FMOC-GLN (trt) -gln (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | FMOC-β-ALA-GLN (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | Fmoc-glu (otbu) -glu (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | FMOC-β-ALA-Glu (OTBU) -oh.H2O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | FMOC-β-ALA-GLY-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | FMOC-HIS (TRT) -HIS (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | FMOC-β-Ala-HIS (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | FMOC-ILE-ILE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | FMOC-β-ALA-ILE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | FMOC-LEU-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | FMOC-β-ALA-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | FMOC-D-LEU-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | FMOC-β-ala-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | Fmoc-lys (boc) -lys (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | FMOC-β-Ala-Lys (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | Fmoc-lys (alloc) -lys (alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | FMOC-β-Ala-Lys (alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | FMOC-Met-Met-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | FMOC-β-Ala-Met-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | Fmoc-orn (boc) -orn (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | FMOC-β-Ala-orn (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | FMOC-PHE-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | FMOC-β-ALA-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | FMOC-D-PHE-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | FMOC-β-Ala-D-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | FMOC-Pro-Pro-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | FMOC-β-ALA-Pro-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | FMOC-SER (TBU) -SER (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | FMOC-β-ala-ser (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | FMOC-SER (TRT) -SER (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | FMOC-β-ala-ser (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | FMOC-thr (tbu) -thr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | FMOC-β-Ala-Thr (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | FMOC-TRP (BOC) -trp (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | FMOC-β-ALA-TRP (BOC) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | FMoc-tyr (tbu) -tyr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | FMOC-β-ALA-Tyr (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | FMOC-D-Tyr (ET) -D-Tyr (ET) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | FMOC-β-Ala-D-Tyr (ET) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | Fmoc-tyr (me) -tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | FMOC-β-ala-tyr (ME) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | Fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | FMOC-β-Ala-Val-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | FMOC-β-Ala-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | FMOC-β-ala-dab-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | FMOC- (3- (2-naphthyl) -d-ala) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | FMOC-β-ALA-3- (2-naphthyl) -d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | FMOC- (3- (3-pyridinyl) -d-ala) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | FMOC-β-ALA-3- (3-pyridinyl) -D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | FMOC- (4-chloro-d-phe) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | FMOC-β-ALA-4-CHLORO-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | FMOC-β-ALA-D-4APH (TBUCBM) -oH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | FMOC-APH (l-hor) -aph (l-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | FMOC-β-ALA-APH (L-HOR) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | FMOC-lys (ipr, boc) -lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | FMOC-β-Ala-Lys (IPR, BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | FMOC-β-ALA-AEEA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | FMOC-AIB-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | FMOC-β-ALA-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | FMOC-Arg-OH | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | H-arg (pbf) -oh | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | FMOC-D-Arg-OH | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | HD-Arg (PBF) -oh | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | FMOC-HOMOARG-OH.HCl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | H-Homoarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | FMOC-D-HOMOARG-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | HD-Homoarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | FMOC-ASN-OH | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-asn (trt) -oh | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | FMOC-ASP-OH | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | H-ASP (OTBU) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | FMOC-CYS-OH | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | H-Cys (trt) -oh | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | H-Cys (ACM) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | FMOC-GLN-OH | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-GLN (trt) -oh | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | FMOC-Glu-OH | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | H-glu (otbu) -oh.H2O | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 100 | FMOC-HIS-OH | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 101 | H-yake (trt) -oh | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 102 | BOC-HIS-OH | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 103 | FMOC-LYS-OH | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 104 | H-lys (boc) -oh | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 105 | H-lys (alloc) -oh | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 106 | FMOC-ORN-OH.HCl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 107 | H-orn (boc) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 108 | FMOC-SER-OH | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 109 | H-ser (tbu) -oh | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 110 | H-ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 111 | FMOC-ThR-OH.H2O | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 112 | H-thr (tbu) -oh | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 113 | FMOC-TRP-OH | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 114 | H-TRP (BOC) -oh | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 116 | HD-TRP (BOC) -oh | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 117 | FMOC-Tyr-OH | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 118 | H-tyr (tbu) -oh | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 119 | FMOC-D-Tyr-OH | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 120 | HD-Tyr (ET) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 121 | H-tyr (mimi) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 122 | FMOC-D-4APH (CBM) -oh | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 123 | HD-4aph (tbucbm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 124 | Fmoc-lys (ipr) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 125 | H-lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
Kuhusu
Fidia
Gentolex hutoa bidhaa bora, ikiwa ubora wowote wa bidhaa umeinuliwa na Mteja ndani ya wakati unaohitajika na ushahidi wa kutosha, tutatoa uchambuzi muhimu na tathmini ili kusababisha taratibu za fidia.
Utendaji
Uwezo wa bidhaa za dawa ulifikia kiwango cha tani, uwezo wa bidhaa za kemikali hufikia 100tons+ daraja, uwezo huo umewekwa vizuri kutumikia wateja ulimwenguni.
Utafiti na Maendeleo
Kila mwaka, kuna mpango uliowekwa na timu ya R&D kukuza bidhaa mpya tofauti, wakati malengo yamewekwa, kila mwanachama kwenye timu atalazimika kuendelea na jukumu la KPI na sera ya motisha.
